The present invention relates to a process for the isolation of pure crystalline imipenem monohydrate wherein the said process comprises crystallizing imipenem monohydrate from a solution, which comprises dissolving imipenem in an organic solvent, aqueous solvent, or a mixture thereof, and crystallizing without using lyophilization, freeze drying or chromatographic techniques at any stage.
Imipenem monohydrate of Formula I as shown in the accompanied drawings which is the N-formimidoyl derivative of thienamycin, is the first clinically available member of new class of p-lactam antibiotics that possess the carbapenem ring system. Imipenem exhibits an extremely broad spectrum of activity against gram-positive and gram-negative aerobic and anaerobic species, which is partly due to its high stability in the presence of p-lactamases.
Imipenem was first obtained by lyophilization technique as disclosed in the U.S. Pat. No. 4,194,047. The product obtained by lyophilization is found to be largely amorphous and stated to be thermodynamically unstable. The process also involves an initial purification through column chromatography using hydrophobic resins.
A thermodynamically stable crystalline monohydrate form of imipenem is disclosed in U.S. Pat. No. 4,260,543 which is obtained by crystallization of a lyophilized sample of imipenem. However, this process is not satisfactory at commercial scale as it requires isolation of the product via column chromatography, lyophilization, followed by crystallization. Moreover, the prolonged process for isolation of final product leads to degradation of imipenem, thus affecting the purity of the product.
In U.S. Patent No. 4,292,436, crystalline imipenem is obtained by purifying the crude product by column chromatography. Further, Crocker et al. have reported in J. Pharm. Sci. 84, 226 (1995) that changes in lyophilization parameters result in varying degrees of crystallinity in the isolated imipenem samples. A variant method for preparing imipenem having a high degree of crystallinity by freeze crystallization process has been reported by Connolly et. al. in J. Pharm. Sci, 85, 174(1996). However, these processes are tedious, cumbersome and unsuitable for industrial use.

The object of the present invention is to provide a simple, practical and efficient method for the preparation of crystalline imipenem monohydrate which is thermally stable, has a uniform degree of crystallinity and high purity.
The present invention relates to a process for the isolation of pure crystalline imipenem monohydrate from a solution containing imipenem. The process does not use capital intensive techniques of lyophilization or freeze crystallization as well as the time consuming purification process of column chromatography using expensive hydrophobic resins. The present invention thus fulfills the need for a process which is convenient to operate on a plant scale.
In particular, the present invention provides a process for the isolation of pure crystalline imipenem monohydrate of Formula I, as shown in the accompanied drawing, which comprises crystallizing imipenem monohydrate from a solution thereof in an organic or aqueous solvent or a mixture thereof, without using lyophilization, freeze drying or chromatographic techniques at any stage.
The solvent system from which the product may be crystallized will desirably be selected from organic solvents which are water-miscible polar organic solvents, optionally alone but preferably in admixture with water.
Examples of such water miscible polar organic solvents include lower alcohols such as methanol, ethanol, propanol and isopropanol; ketones such as acetone; glycol ethers such as monoethylene glycol; amides such as N, N-dimethylformamide, N, N-dimethylacetamide; lactams such as N-methylpyrrolidone and cyclic ethers such as tetrahydrofuran, dioxane, or mixture(s) thereof. Particularly preferred is isopropanol.
The crystallization step will desirably be carried out at low temperatures, for example at about 0°C to about 15°C, and the concentration of imipenem in the solution from which crystallization will occur will generally be adjusted e.g. by evaporation of solvent or by dilution so as to be neither too dilute nor too concentrated, respectively.

The crystallization may comprise the last stage or stages of a reaction in which the imipenem is formed. The reaction in which the imipenem is formed may be carried out by following any of the synthetic routes described in the prior art viz. US 4,194,047, US 4,292,436, US 4,374,772 or US 4,894,450 and are incorporated herein by reference, but will preferably be carried out in the manner described in the patent application filed concurrently herewith and exemplified as example 1 in this patent application.
Before carrying out the process of crystallization, the solution containing imipenem may be washed with an organic solvent having limited miscibility in water to remove organic impurities.
Also, pH of the solution of imipenem is adjusted, if required, to about 7 to 8 before washings to facilitate removal of impurities.
In the meaning of the present invention, the term "limited miscibility" shall also include water-immiscible solvents. Examples of such organic solvents include carboxylic acid esters such as ethyl acetate, higher alkyl ketones such as methylisobutyl ketone, chlorinated hydrocarbons such as dichloromethane, ethers such as diethyl ether, aromatic hydrocarbons such as toluene, and mixture(s) thereof. Particularly, preferred are dichloromethane and ethyl acetate.
Accordingly, the present invention relates to a process for the isolation of pure crystalline imipenem monohydrate of Formula I, as shown in the accompanied drawing, wherein the said process comprises crystallizing imipenem monohydrate from a solution, which comprises dissolving imipenem in an organic solvent, aqueous solvent, or a mixture thereof, and crystallizing at a temperature from 0°C to 15°C, without using lyophilization, freeze drying or chromatographic techniques at any stage.
In the following section preferred embodiments are described by way of examples to illustrate the process of the invention. However, these are not intended in any way to limit the scope of the present invention.

Example 1
Step (a) - Preparation of enol phosphate intermediate
p-Nitrobenzyl (3R, 5R, 6S)-2oxo-6-[(1R)-1-hydroxyethyl)] carbapenem-3-carboxylate
(30g) was dissolved in a mixture of N, N-dimethylacetamide (300ml) and
dichloromethane (150ml). The solution was cooled to -55°C and
dimethylaminopyridine (0.17g) was added followed by diisopropylethylamine (26.7g). The mixture was stirred for 5 minutes at about -55°C and then a solution of diphenylchlorophosphate (25.4g) in dichloromethane (30ml) was added dropwise at -55 to -45°C. The reaction was stirred further for 30 minutes to obtain the enol phosphate ester.
Step (b) - Preparation of thienamycin ester
The reaction mixture from step (a) was further cooled to -70 to -75°C and a solution of 2-aminoethanethiol hydrochloride (12g) in N, N-dimethylacetamide (60ml) was added in 10 minutes at -75 to -60°C. The reaction mixture was stirred for another 60 minutes to produce p-nitrobenzyl ester of thienamycin.
Step (c) - Preparation of p-nitrobenzyl ester of imipenem
To the above reaction mixture from step (b), was added diisopropylethylamine (16.0g) and benzyl formimidate hydrochloride (20.0g) at -50 to -55°C. The reaction was allowed to continue for about one and a half hour at the same temperature. The temperature was then raised to -20°C and the reaction mixture was stirred for 20-30 minutes at this temperature to obtain a clear solution of imipenem ester.
Step (d) - Preparation of imipenem
The above clear solution obtained from step (c) was poured into a mixture of water (300ml), isopropanol (150ml) and N-methylmorpholine (26g) maintained at 5-10°C and the pH of the solution adjusted to 7.0 to 7.5. The solution was hydrogenated at

3-4 kg pressure for 2.5 hours at 10-25°C over palladium-charcoal. The mixture was filtered and assayed for imipenem (80%, as determined by HPLC).
ISOLATION OF CRYSTALLINE IMIPENEM MONOHYDRATE
Example 2
The reaction mixture containing imipenem obtained at step (d ) Example 1 was stirred with dichloromethane (900ml) maintaining pH between 7.0 to 8.0 and the aqueous layer separated. The aqueous portion was degassed to remove dichloromethane and given activated carbon treatment. The filtered aqueous solution was mixed with isopropanol (400ml) and stirred at 5-10°C for 3 hours . The crystalline product so obtained was filtered, washed with isopropropanol followed by acetone and dried at 35-40°C for 1 hour to obtain crystalline imipenem monohydrate (9.0g, purity 99% by HPLC).
Example 3
The process of Example 2 was repeated using acetone (400ml) instead of isopropanol during crystallization. Crystalline imipenem monohydrate (8.0g) was obtained in 99% purity (by HPLC).
Example 4
The aqueous portion obtained as in Example 2 was concentrated to 200ml. The aqueous solution so obtained was given carbon treatment at 5-10°C and the filtered solution was stirred with acetone (400ml) at 5-10°C for 3 hours to obtain crystalline imipenem monohydrate after filtration and drying (12.0g, purity 98 - 99% by HPLC).

WE CLAIM:
1. A process for the isolation of pure crystalline imipenem monohydrate of Formula I, as shown in the accompanied drawing, wherein the said process comprises crystallizing imipenem monohydrate from a solution, which comprises dissolving imipenem in an organic solvent, aqueous solvent, or a mixture thereof, and crystallizing at a temperature from 0°C to 15°C, without using lyophilization, freeze drying or chromatographic techniques at any stage.
2. The process as claimed in claim 1 wherein the organic solvent comprises a water-miscible polar organic solvent.
3. The process as claimed in claims 1 and 2 wherein the organic solvent comprises an admixture of water-miscible polar organic solvent with water.
4. The process as claimed in claim 2 wherein the water-miscible polar organic solvent comprises a lower alcohol, glycol ether, amide, lactam, cyclic ether, or a mixture thereof.
5. The process as claimed in claim 4 wherein the said organic solvent is selected from the group consisting of methanol, ethanol, propanol, isopropanol, acetone, monoethylene glycol, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, tetrahydrofuran, dioxane and mixture(s) thereof.
6. The process for the isolation of pure crystalline imipenem monohydrate as herein described and illustrated by the examples herein.